Mountain State Medical Policy Bulletin

Section: Injections
Number: I-8
Topic: Immunizations
Effective Date: October 15, 2007
Issued Date: October 15, 2007
Date Last Reviewed: 10/2007

General Policy Guidelines

Indications and Limitations of Coverage

The following American Academy of Pediatrics recommended immunizations are covered for individuals who are up to and including 17 years of age for the following diseases:

Diphtheria
Hemophilus Influenza B (HIB)
Hepatitis A
Hepatitis B
Influenza
Meningitis
Mumps
Pertussis (whooping cough)
Pneumonia
Polio
Rubella
Rubeola (measles)
Tetanus
Varicella

NOTE:
Refer to Medical Policy Bulletin I-20 for eligibility guidelines on RSV treatment.

COMVAX (90748), a combination of the hemophilus influenza B (HIB) and hepatitis B vaccines, is a covered immunization procedure.

Pediarix™ (90723), a combination of the DtaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), Hepatitis B Vaccine (Recombinant), and Inactivated Poliovirus Vaccine (IPV) for administration as one intramuscular injection, is a covered immunization procedure.

Boostrix® (90715) is a combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap). Boostrix is a covered immunization procedure given as a single dose to individuals aged 10 to 18 years.

AdacelTM (90715) is a combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap). Adacel is a covered immunization procedure given as a single dose to individuals aged 11 to 64 years.

ProQuad® (90710) is a combination vaccine of M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) and VARIVAX® (Varicella Virus Vaccine Live). It is indicated for simultaneous vaccination against all four of these diseases in children 12 months to 12 years of age.

Furthermore, reported combinations of the above vaccines are also eligible for payment, e.g., DPT (diphtheria and tetanus toxoids plus pertussis vaccine) is a commonly used combined immunization procedure.

NOTE:
The following codes are applicable to the childhood immunizations listed above: (90633, 90634, 90645, 90646, 90647, 90648, 90655, 90656, 90657, 90658, 90660, 90669, 90698, 90700, 90701, 90702, 90704, 90705, 90706, 90707, 90708, 90710, 90712, 90713, 90714, 90715, 90716, 90718, 90719, 90720, 90721, 90723, 90732, 90733, 90734, 90743, 90744, 90748, S0195). 

NOTE:

FluMist (90660) is an intranasal live virus influenza vaccine for healthy children and adolescents, ages five years to 17 years, and healthy adults, ages 18 to 49. This vaccine is generally not covered. However, coverage may be provided during shortages of the injectable vaccine. A participating, preferred, or network provider can bill the member for the denied service.

 

OTHER IMMUNIZATIONS

Other than those specific childhood immunizations listed above, coverage for immunizations is determined according to individual or group customer benefits. Immunizations should be reported under the appropriate procedure code. Immunization is acceptable for the following diseases:

Adenovirus
Anthrax
Bladder Cancer
Cholera
Diphtheria
Hemophilus Influenza B (HIB)
Hepatitis A
Hepatitis B

Herpes Zoster (Shingles)
Influenza

Japanese Encephalitis
Lyme Disease
Meningitis
Mumps
Pertussis (whooping cough)
Pneumonia
Plague
Polio
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Rabies
Rotavirus
Rubella
Rubeola (measles)
Tetanus
Tuberculosis
Typhoid Fever
Varicella

Yellow Fever

DPT (diphtheria and tetanus toxoids plus pertussis vaccine) is a commonly used combined immunization procedure.

Twinrix® (90636), a combination of the hepatitis A virus (HAV; HAVRIX®) and hepatitis B virus (HBV; Energix-B®) vaccines, is a covered immunization procedure for individuals 18 years of age or older.

AdacelTM (90715) is a combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap). Adacel is a covered immunization procedure given as a single dose to individuals aged 11 to 64 years.

NOTE:

In addition to the procedure codes listed under the childhood immunizations, the following codes are applicable to the other immunizations: (90476, 90477, 90581, 90585, 90586, 90632, 90636, 90645, 90646, 90647, 90648, 90649, 90656, 90658, 90660, 90665, 90675, 90676, 90680, 90690-90693, 90698, 90701, 90703, 90704, 90705, 90706, 90707, 90708, 90710, 90712, 90713, 90714, 90715, 90716, 90717, 90718, 90719, 90720, 90721, 90723, 90725, 90727, 90732, 90733, 90734, 90735, 90736, 90740, 90746, 90747, 90748, and 90749).

FluMist (90660) is an intranasal live virus influenza vaccine for healthy children and adolescents, ages five years to 17 years, and healthy adults, ages 18 to 49. This vaccine is generally not covered. However, coverage may be provided during shortages of the injectable vaccine. A participating, preferred, or network provider can bill the member for the denied service.

Immunizations or injections for diseases other than those listed above are not eligible for payment. 

NOTE:
A separate administration fee can be reported with each separately administered immunization. Codes 90465-90468, 90471-90474 and G0008-G0010 should be reported as appropriate in addition to immunization procedure codes. (This applies to all patients, regardless of age, who have coverage for immunizations.) If codes 90465-90468, 90471-90474, G0008-G0010 are reported as the sole service they will be eligible for payment.

A separate Evaluation & Management (E&M) code can be reported in addition to the administration of an immunization if a significant, separately identifiable E&M service is performed and documented in the patient's medical records.  To justify these services, the patient's records must contain sufficient documentation regarding the appropriateness of performing both services, and documentation that the key components of the E&M service have been met.  If the reported E&M service does not meet the component requirements, it will not be eligible for reimbursement.  Payment for the immunization and the E&M service does not meet the component requirements, it will not be eligible for reimbursement.  Payment for the immunization and the E&M service will also be subject to coverage limitations specified within the individual member's contract. 

See Medical Policy Bulletin I-15 on Hepatitis B vaccine for adults.


NOTE:
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Procedure Codes

904659046690467904689047190472
904739047490585906329063390634
906369064590646906479064890649
906559065690657906589066090669
906759067690680906909069190692
907009070190702907039070490705
907069070790708907109071290713
907149071590716907179071890719
907209072190723907259072790732
907339073490735907369074090743
9074490746907479074890749G0008
G0009G0010J1562Q4090S0195 

Traditional Guidelines

Refer to General Policy Guidelines

FEP Guidelines

Routine immunizations (as licensed by the U.S. Food and Drug Administration), without regard to age, limited to:

  • Hepatitis immunization (Types A and B) for patients with increased risk or family history
  • Influenza (one each flu season) and pneumococcal vaccines
  • Tetanus-diphtheria (Td) booster - once every 10 years
  • Herpes Zoster (shingles) vaccines
  • Human Papillomavirus (HPV) vaccines

Routine services as recommended by the American Academy of Pediatrics for children up to the age of 22, including children living, traveling, or adopted from outside the United States:

  • Meningococcal vaccine
  • Human Papillomavirus (HPV) vaccines
  • Rotavirus vaccines
  • Immunizations

PPO Guidelines

Refer to General Policy Guidelines

Managed Care POS Guidelines

Refer to General Policy Guidelines

Publications

References

Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Morbidity/Mortality Weekly Report, 49 (RR-03); 1-38, 4/2000

Control and Prevention of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Morbidity/Mortality Weekly Report, 46 (RR-5); 1-51, 2/1997

Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Morbidity/Mortality Report, 46 (RR-08); 1-24, 4/1997

Immunizations of Adolescents: Recommendations of the Advisory Committee on Immunization Practices, The American Academy of Pediatrics, The American Academy of Family Physicians, and the American Medical Association, American Academy of Pediatrics, Vol. 99, No. 3, 3/1997

Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis (RE9960), American Academy of Pediatrics, Policy Statement, Vol. 106, No. 02, August, 2000 Act 35 of 1992

Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and Adults, JAMA,, Vol. 293, No. 24, June 2005

View Previous Versions

[Version 008 of I-8]
[Version 007 of I-8]
[Version 006 of I-8]
[Version 005 of I-8]
[Version 004 of I-8]
[Version 003 of I-8]
[Version 002 of I-8]
[Version 001 of I-8]

Table Attachment

Text Attachment

Procedure Code Attachment


Glossary





This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Medical policies are designed to supplement the terms of a member's contract. The member's contract defines the benefits available; therefore, medical policies should not be construed as overriding specific contract language. In the event of conflict, the contract shall govern.

Medical policies do not constitute medical advice, nor the practice of medicine. Rather, such policies are intended only to establish general guidelines for coverage and reimbursement under Mountain State Blue Cross Blue Shield plans. Application of a medical policy to determine coverage in an individual instance is not intended and shall not be construed to supercede the professional judgment of a treating provider. In all situations, the treating provider must use his/her professional judgment to provide care he/she believes to be in the best interest of the patient, and the provider and patient remain responsible for all treatment decisions.

Mountain State Blue Cross Blue Shield (MSBCBS) retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of MSBCBS. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.